Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
THX PharmaSTU:3VG -1.03%39 10-Year RORE % is -6.20 as of Dec. 2025. GuruFocus rates STU:3VG with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 615 Biotechnology companies, THX Pharma ranks better than 50.41% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
THX Pharma's 10-Year RORE % for the quarter that ended in Dec. 2025 was -6.20%.
The industry rank for THX Pharma's 10-Year RORE % or its related term are showing as below:
STU:3VG's 10-Year RORE % is ranked better than 50.41% of 615
companies
in the Biotechnology industry
Industry Median: -6.37
vs STU:3VG: -6.20
THX Pharma (STU:3VG) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
THX Pharma 10-Year RORE % Related Terms
THX Pharma 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for THX Pharma's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:3VG vs VRTX, REGN, ALNY: 10-Year RORE % Comparison
For the Biotechnology subindustry, THX Pharma's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
THX Pharma 10-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, THX Pharma's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where THX Pharma's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 10-year before.
THX Pharma (STU:3VG) has a 10-Year RORE % of -6.20 as of Dec. 2025. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #305 out of 615 companies in the Biotechnology industry, placing it in the top 49.6%.
Is THX Pharma's 10-Year RORE % too high?
THX Pharma's current 10-Year RORE % is -6.20. Based on the distribution chart, THX Pharma ranks #305 out of 615 companies in the Biotechnology industry, which is above the industry midpoint. Overall, THX Pharma has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's 10-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #305 out of 615 companies for 10-Year RORE %. This puts THX Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Biotechnology company?
A good 10-Year RORE % depends on the Biotechnology industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on THX Pharma and its competitors. THX Pharma's current 10-Year RORE % is -6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (STU:3VG) has a current 10-Year RORE % of -6.20. The current 10-Year RORE % is -6.20. THX Pharma's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For THX Pharma (STU:3VG), the current 10-Year RORE % is -6.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
39GF Score
Get the complete analysis for STU:3VG
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3VG has been successfully added to your 
